Mirum Pharmaceuticals director Carol Brosgart resigns, becomes senior advisor; Lon Cardon appointed to board
Mirum Pharmaceuticals, Inc.
Carol L. Brosgart resigned as director and Nominating Committee member effective Dec 19, 2022; no dispute; becomes senior advisor in science and policy.
Lon Cardon, Ph.D., appointed to board as Class I director, term expiring at 2023 annual meeting, and to Nominating and Corporate Governance Committee.
Cardon receives option for 34,000 shares vesting in 3 equal annual installments, plus annual cash retainer of $40,000 ($4,000 for committee service) prorated for 2022.
Cardon eligible for annual option grant of 17,000 shares starting at 2023 annual meeting, prorated per policy.
Standard indemnification agreement entered; no arrangements with other persons for selection.
On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.
On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Carol L. Brosgart resigned as Director at Mirum Pharmaceuticals, Inc..
Action
resigned
Role
Director
Exact text from the filing
On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.
Lon Cardon was appointed as Director at Mirum Pharmaceuticals, Inc..
Action
appointed
Role
Director
Exact text from the filing
On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.